What is HC Wainwright’s Forecast for LXEO FY2024 Earnings?

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Research analysts at HC Wainwright reduced their FY2024 earnings per share estimates for shares of Lexeo Therapeutics in a report released on Thursday, November 14th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($3.22) for the year, down from their prior forecast of ($2.75). HC Wainwright currently has a “Buy” rating and a $23.00 target price on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.05) per share. HC Wainwright also issued estimates for Lexeo Therapeutics’ Q4 2024 earnings at ($0.90) EPS, Q1 2025 earnings at ($0.93) EPS, Q2 2025 earnings at ($0.94) EPS, Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($1.00) EPS and FY2025 earnings at ($3.84) EPS.

A number of other equities analysts also recently issued reports on the company. Chardan Capital raised their price target on Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Leerink Partners lowered their target price on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 13th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $24.00 target price on shares of Lexeo Therapeutics in a research report on Tuesday, August 13th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Lexeo Therapeutics presently has a consensus rating of “Buy” and an average target price of $22.71.

Lexeo Therapeutics Stock Performance

LXEO stock opened at $6.65 on Monday. The company has a market cap of $219.92 million and a P/E ratio of -2.10. Lexeo Therapeutics has a 1 year low of $6.65 and a 1 year high of $22.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 9.38. The stock’s fifty day moving average price is $9.01 and its 200-day moving average price is $12.23.

Institutional Investors Weigh In On Lexeo Therapeutics

Several large investors have recently made changes to their positions in the company. Bank of New York Mellon Corp increased its holdings in shares of Lexeo Therapeutics by 12.3% in the second quarter. Bank of New York Mellon Corp now owns 31,806 shares of the company’s stock worth $510,000 after purchasing an additional 3,483 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Lexeo Therapeutics by 184.2% during the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock worth $50,000 after acquiring an additional 3,591 shares during the last quarter. Rhumbline Advisers increased its stake in Lexeo Therapeutics by 37.3% during the second quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock worth $214,000 after acquiring an additional 3,627 shares during the last quarter. American International Group Inc. bought a new stake in Lexeo Therapeutics during the first quarter worth approximately $79,000. Finally, Values First Advisors Inc. bought a new stake in Lexeo Therapeutics during the third quarter worth approximately $67,000. 60.67% of the stock is owned by institutional investors.

Insider Transactions at Lexeo Therapeutics

In other news, CEO Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $10.65, for a total value of $53,250.00. Following the sale, the chief executive officer now directly owns 120,695 shares of the company’s stock, valued at approximately $1,285,401.75. The trade was a 3.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders have sold 12,500 shares of company stock valued at $113,300. 4.50% of the stock is currently owned by insiders.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.